Orally desensitized mast cells form a regulatory network with Treg cells for the control of food allergy.

Administration, Oral Allergens / immunology Animals Cell Communication Cell Degranulation Desensitization, Immunologic / methods Disease Models, Animal Female Food Hypersensitivity / immunology Immune Tolerance Immunomodulation Mast Cells / immunology Mice Mice, Inbred BALB C T-Lymphocytes, Regulatory / immunology

Journal

Mucosal immunology
ISSN: 1935-3456
Titre abrégé: Mucosal Immunol
Pays: United States
ID NLM: 101299742

Informations de publication

Date de publication:
05 2021
Historique:
received: 13 01 2020
accepted: 21 10 2020
revised: 09 10 2020
pubmed: 11 12 2020
medline: 21 12 2021
entrez: 10 12 2020
Statut: ppublish

Résumé

Oral immunotherapy (OIT) is an effective approach to controlling food allergy. Although the detailed molecular and cellular mechanisms of OIT are unknown currently, they must be understood to advance the treatment of allergic diseases in general. To elucidate the mechanisms of OIT, especially during the immunological transition from desensitization to allergy regulation, we generated a clinical OIT murine model and used it to examine immunological events of OIT. We found that in mice that completed OIT successfully, desensitized mast cells (MCs) showed functionally beneficial alterations, such as increased induction of regulatory cytokines and enhanced expansion of regulatory T cells. Importantly, these regulatory-T-cell-mediated inhibitions of allergic responses were dramatically decreased in mice lacking OIT-induced desensitized MC. Collectively, these findings show that the desensitization process modulates the activation of MCs, leading directly to enhanced induction of regulatory-T-cell expansion and promotion of clinical allergic unresponsiveness. Our results suggest that efficiently inducing regulatory MCs is a novel strategy for the treatment of allergic disease.

Identifiants

DOI: 10.1038/s41385-020-00358-3 PMID: 33299086 PMC: PMC8075951
pubmed: 33299086
doi: 10.1038/s41385-020-00358-3
pii: S1933-0219(22)00165-9
pmc: PMC8075951
doi:

Substances chimiques

Allergens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

640-651

Références

Longo, G., Berti, I., Burks, A. W., Krauss, B. & Barbi, E. IgE-mediated food allergy in children. Lancet 382, 1656–1664 (2013).
pubmed: 23845860 doi: 10.1016/S0140-6736(13)60309-8
Sicherer, S. H. Epidemiology of food allergy. J. Allergy Clin. Immunol. 127, 594–602 (2011).
pubmed: 21236480 doi: 10.1016/j.jaci.2010.11.044
Lieberman, P. et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J. Allergy Clin. Immunol. 126, 477–480.e471-442 (2010).
pubmed: 20692689 doi: 10.1016/j.jaci.2010.06.022
Yamani A., et al. Dysregulation of intestinal epithelial CFTR-dependent Cl(-) ion transport and paracellular barrier function drives gastrointestinal symptoms of food-induced anaphylaxis in mice. Mucosal Immunol. https://doi.org/10.1038/s41385-020-0306-6 . [Ebup ahead of print] (2020).
Melendez, A. J. et al. Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes. Nat. Med. 13, 1375–1381 (2007).
pubmed: 17952092 doi: 10.1038/nm1654
Galli, S. J. & Tsai, M. IgE and mast cells in allergic disease. Nat. Med. 18, 693–704 (2012).
pubmed: 22561833 pmcid: 3597223 doi: 10.1038/nm.2755
Brown, S. G. et al. Anaphylaxis: clinical patterns, mediator release, and severity. J. Allergy Clin. Immunol. 132, 1141–1149.e1145 (2013).
pubmed: 23915715 doi: 10.1016/j.jaci.2013.06.015
Soter, N. A., Austen, K. F. & Wasserman, S. I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N. Engl. J. Med. 301, 465–469 (1979).
pubmed: 111124 doi: 10.1056/NEJM197908303010903
Harvima, I. T. et al. Molecular targets on mast cells and basophils for novel therapies. J. Allergy Clin. Immunol. 134, 530–544 (2014).
pubmed: 24767877 doi: 10.1016/j.jaci.2014.03.007
McLeod, J. J., Baker, B. & Ryan, J. J. Mast cell production and response to IL-4 and IL-13. Cytokine 75, 57–61 (2015).
pubmed: 26088754 pmcid: 4532630 doi: 10.1016/j.cyto.2015.05.019
Kurashima, Y. et al. Sphingosine 1-phosphate-mediated trafficking of pathogenic Th2 and mast cells for the control of food allergy. J. Immunol. 179, 1577–1585 (2007).
pubmed: 17641024 doi: 10.4049/jimmunol.179.3.1577
Kweon, M. N., Yamamoto, M., Kajiki, M., Takahashi, I. & Kiyono, H. Systemically derived large intestinal CD4(+) Th2 cells play a central role in STAT6-mediated allergic diarrhea. J. Clin. Investig. 106, 199–206 (2000).
pubmed: 10903335 pmcid: 314304 doi: 10.1172/JCI8490
Akdis, M. & Akdis, C. A. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J. Allergy Clin. Immunol. 133, 621–631 (2014).
pubmed: 24581429 doi: 10.1016/j.jaci.2013.12.1088
Larche, M., Akdis, C. A. & Valenta, R. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6, 761–771 (2006).
pubmed: 16998509 doi: 10.1038/nri1934
Blumchen, K. et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J. Allergy Clin. Immunol. 126, 83–91.e81 (2010).
pubmed: 20542324 doi: 10.1016/j.jaci.2010.04.030
Wood, R. A. Oral Immunotherapy for Food Allergy. J. Investig. Allergol. Clin. Immunol. 27, 151–159 (2017).
pubmed: 28102823 doi: 10.18176/jiaci.0143
Chinthrajah, R. S., Hernandez, J. D., Boyd, S. D., Galli, S. J. & Nadeau, K. C. Molecular and cellular mechanisms of food allergy and food tolerance. J. Allergy Clin. Immunol. 137, 984–997 (2016).
pubmed: 27059726 pmcid: 5030841 doi: 10.1016/j.jaci.2016.02.004
Burks, A. W. et al. Oral immunotherapy for treatment of egg allergy in children. N. Engl. J. Med. 367, 233–243 (2012).
pubmed: 22808958 pmcid: 3424505 doi: 10.1056/NEJMoa1200435
Leveson-Gower, D. B. et al. Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. Blood 122, 3659–3665 (2013).
pubmed: 24030387 pmcid: 3837515 doi: 10.1182/blood-2013-08-519157
Morita, H. et al. An Interleukin-33-Mast Cell-Interleukin-2 Axis Suppresses Papain-Induced Allergic Inflammation by Promoting Regulatory T Cell Numbers. Immunity 43, 175–186 (2015).
pubmed: 26200013 pmcid: 4533925 doi: 10.1016/j.immuni.2015.06.021
Galli, S. J. et al. Approaches for analyzing the roles of mast cells and their proteases in vivo. Adv. Immunol. 126, 45–127 (2015).
pubmed: 25727288 pmcid: 4771191 doi: 10.1016/bs.ai.2014.11.002
Sawaguchi, M. et al. Role of mast cells and basophils in IgE responses and in allergic airway hyperresponsiveness. J. Immunol. 188, 1809–1818 (2012).
pubmed: 22250079 doi: 10.4049/jimmunol.1101746
Keet, C. A. et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J. Allergy Clin. Immunol. 129, 448–455 (2012). 455 e441-445.
pubmed: 22130425 doi: 10.1016/j.jaci.2011.10.023
Khodoun, M. V. et al. Rapid polyclonal desensitization with antibodies to IgE and FcepsilonRIalpha. J. Allergy Clin. Immunol. 131, 1555–1564 (2013).
pubmed: 23632296 pmcid: 4341981 doi: 10.1016/j.jaci.2013.02.043
Kurashima, Y. et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat. Commun. 3, 1034 (2012).
pubmed: 22948816 doi: 10.1038/ncomms2023
Dawicki, W., Li, C., Town, J., Zhang, X. & Gordon, J. R. Therapeutic reversal of food allergen sensitivity by mature retinoic acid-differentiated dendritic cell induction of LAG3+CD49b-Foxp3- regulatory T cells. J. Allergy Clin. Immunol. 139, 1608–1620.e1603 (2017).
pubmed: 28277274 doi: 10.1016/j.jaci.2016.07.042
Noval Rivas, M. & Chatila, T. A. Regulatory T cells in allergic diseases. J. Allergy Clin. Immunol. 138, 639–652 (2016).
pubmed: 27596705 doi: 10.1016/j.jaci.2016.06.003
Takayama, N., Igarashi, O., Kweon, M. N. & Kiyono, H. Regulatory role of Peyer’s patches for the inhibition of OVA-induced allergic diarrhea. Clin. Immunol. 123, 199–208 (2007).
pubmed: 17360239 doi: 10.1016/j.clim.2007.01.007
Mabbott, N. A., Donaldson, D. S., Ohno, H., Williams, I. R. & Mahajan, A. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 6, 666–677 (2013).
pubmed: 23695511 pmcid: 3686595 doi: 10.1038/mi.2013.30
Esterhazy, D. et al. Classical dendritic cells are required for dietary antigen-mediated induction of peripheral T(reg) cells and tolerance. Nat. Immunol. 17, 545–555 (2016).
pubmed: 27019226 pmcid: 4837106 doi: 10.1038/ni.3408
de Vries, V. C. et al. Mast cells condition dendritic cells to mediate allograft tolerance. Immunity 35, 550–561 (2011).
pubmed: 22035846 pmcid: 3753083 doi: 10.1016/j.immuni.2011.09.012
Rodrigues, C. P. et al. Tolerogenic IDO(+) Dendritic Cells Are Induced by PD-1-Expressing Mast Cells. Front. Immunol. 7, 9 (2016).
pubmed: 26834749 pmcid: 4724729 doi: 10.3389/fimmu.2016.00009
Feng, B. S. et al. Disruption of T-cell immunoglobulin and mucin domain molecule (TIM)-1/TIM4 interaction as a therapeutic strategy in a dendritic cell-induced peanut allergy model. J. Allergy Clin. Immunol. 122, 55–61 (2008). 61 e51-57.
pubmed: 18547633 doi: 10.1016/j.jaci.2008.04.036
Mazzini, E., Massimiliano, L., Penna, G. & Rescigno, M. Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1(+) macrophages to CD103(+) dendritic cells. Immunity 40, 248–261 (2014).
pubmed: 24462723 doi: 10.1016/j.immuni.2013.12.012
Salamon, P. et al. IL-33 and IgE stimulate mast cell production of IL-2 and regulatory T cell expansion in allergic dermatitis. Clin. Exp. Allergy 47, 1409–1416 (2017).
pubmed: 28892206 doi: 10.1111/cea.13027
Lu, L. F. et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442, 997–1002 (2006).
pubmed: 16921386 doi: 10.1038/nature05010
Oka, T., Rios, E. J., Tsai, M., Kalesnikoff, J. & Galli, S. J. Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells. J. Allergy Clin. Immunol. 132, 922–932.e921-916 (2013).
pubmed: 23810240 pmcid: 3789647 doi: 10.1016/j.jaci.2013.05.004
Sancho-Serra Mdel, C., Simarro, M. & Castells, M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization. Eur. J. Immunol. 41, 1004–1013 (2011).
pubmed: 21360700 doi: 10.1002/eji.201040810
Suzuki, H. et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268, 1472–1476 (1995).
pubmed: 7770771 doi: 10.1126/science.7770771
Sadlack, B. et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25, 3053–3059 (1995).
pubmed: 7489743 doi: 10.1002/eji.1830251111
Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu Rev. Immunol. 30, 531–564 (2012).
pubmed: 22224781 pmcid: 6066374 doi: 10.1146/annurev.immunol.25.022106.141623
Burton, O. T., Tamayo, J. M., Stranks, A. J., Koleoglou, K. J. & Oettgen, H. C. Allergen-specific IgG antibody signaling through FcgammaRIIb promotes food tolerance. J. Allergy Clin. Immunol. 141, 189–201.e183 (2018).
pubmed: 28479335 doi: 10.1016/j.jaci.2017.03.045
Tunis, M. C., Dawicki, W., Carson, K. R., Wang, J. & Marshall, J. S. Mast cells and IgE activation do not alter the development of oral tolerance in a murine model. J. Allergy Clin. Immunol. 130, 705–715.e701 (2012).
pubmed: 22607990 doi: 10.1016/j.jaci.2012.04.011
Bonnet, B. et al. Low-Dose IL-2 Induces Regulatory T Cell-Mediated Control of Experimental Food Allergy. J. Immunol. 197, 188–198 (2016).
pubmed: 27259854 doi: 10.4049/jimmunol.1501271
Mizui, M. & Tsokos, G. C. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. Front. Immunol. 9, 786 (2018).
pubmed: 29755456 pmcid: 5932391 doi: 10.3389/fimmu.2018.00786
He, X., Koenen, H. J., Slaats, J. H. & Joosten, I. Stabilizing human regulatory T cells for tolerance inducing immunotherapy. Immunotherapy 9, 735–751 (2017).
pubmed: 28771099 doi: 10.2217/imt-2017-0017
Xie, M. M. et al. T follicular regulatory cells and IL-10 promote food antigen-specific IgE. J. Clin. Investig. 130, 3820–3832 (2020).
pubmed: 32255767 pmcid: 7324176 doi: 10.1172/JCI132249
Gowthaman U., et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science. 365 eaaw6433 (2019).
pubmed: 31371561 pmcid: 6901029 doi: 10.1126/science.aaw6433
Chan, C. Y., StJohn, A. L. & Abraham, S. N. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 38, 349–359 (2013).
pubmed: 23415912 pmcid: 3647685 doi: 10.1016/j.immuni.2012.10.019
Grimbaldeston, M. A., Nakae, S., Kalesnikoff, J., Tsai, M. & Galli, S. J. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat. Immunol. 8, 1095–1104 (2007).
pubmed: 17767162 doi: 10.1038/ni1503
Chong, H. J. et al. IL-4 selectively enhances FcgammaRIII expression and signaling on mouse mast cells. Cell Immunol. 224, 65–73 (2003).
pubmed: 14609572 doi: 10.1016/j.cellimm.2003.08.004
Caubet, J. C. et al. Significance of ovomucoid- and ovalbumin-specific IgE/IgG(4) ratios in egg allergy. J. Allergy Clin. Immunol. 129, 739–747 (2012).
pubmed: 22277199 doi: 10.1016/j.jaci.2011.11.053
Galand, C. et al. IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells. J. Allergy Clin. Immunol. 138, 1356–1366 (2016).
pubmed: 27372570 pmcid: 5099088 doi: 10.1016/j.jaci.2016.03.056
Ang, W. X. et al. Mast cell desensitization inhibits calcium flux and aberrantly remodels actin. J. Clin. Investig. 126, 4103–4118 (2016).
pubmed: 27669462 pmcid: 5096925 doi: 10.1172/JCI87492
Kurashima, Y. et al. The Enzyme Cyp26b1 Mediates Inhibition of Mast Cell Activation by Fibroblasts to Maintain Skin-Barrier Homeostasis. Immunity 40, 530–541 (2014).
pubmed: 24726878 doi: 10.1016/j.immuni.2014.01.014
Kunisawa, J. et al. Dietary omega3 fatty acid exerts anti-allergic effect through the conversion to 17,18-epoxyeicosatetraenoic acid in the gut. Sci. Rep. 5, 9750 (2015).
pubmed: 26065911 pmcid: 4464255 doi: 10.1038/srep09750
Leonard, S. A., Martos, G., Wang, W., Nowak-Wegrzyn, A. & Berin, M. C. Oral immunotherapy induces local protective mechanisms in the gastrointestinal mucosa. J. Allergy Clin. Immunol. 129, 1579–1587.e1571 (2012).
pubmed: 22554705 pmcid: 3367084 doi: 10.1016/j.jaci.2012.04.009
Watanabe, H. et al. Heat treatment of egg white controls allergic symptoms and induces oral tolerance to ovalbumin in a murine model of food allergy. Mol. Nutr. Food Res. 58, 394–404 (2014).
pubmed: 23983060 doi: 10.1002/mnfr.201300205
Code, C. F., Higgins, J. A. & Orvis, A. L. The influence of motility on the rate of absorption of sodium and water from the small intestine of healthy persons. Gastroenterology 31, 708–715 (1956). discussion, 715-706.
pubmed: 13397696 doi: 10.1016/S0016-5085(19)35813-5
Onodera, A. et al. Menin Controls the Memory Th2 Cell Function by Maintaining the Epigenetic Integrity of Th2 Cells. J. Immunol. 199, 1153–1162 (2017).
pubmed: 28659357 doi: 10.4049/jimmunol.1602129
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
pubmed: 19261174 pmcid: 2690996 doi: 10.1186/gb-2009-10-3-r25
Feng J., Liu T., Zhang Y. Using MACS to identify peaks from ChIP-Seq data. Curr. Protoc. Bioinform. Chapter 2: Unit 2.14 622-633 (2011).
Fujisawa, D. et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J. Allergy Clin. Immunol. 134, 622–633.e629 (2014).
pubmed: 24954276 doi: 10.1016/j.jaci.2014.05.004
Takamori, A. et al. Identification of inhibitory mechanisms in pseudo-allergy involving Mrgprb2/MRGPRX2-mediated mast cell activation. J. Allergy Clin. Immunol. 143, 1231–1235.e1212 (2019).
pubmed: 30414859 doi: 10.1016/j.jaci.2018.10.034

Auteurs

Yoshihiro Takasato (Y)

Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Department of Pediatrics, Keio University School of Medicine, Tokyo, 160-8582, Japan.

Yosuke Kurashima (Y)

Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan. yosukek@ims.u-tokyo.ac.jp.
Department of Innovative Medicine and Mucosal Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. yosukek@ims.u-tokyo.ac.jp.
International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan. yosukek@ims.u-tokyo.ac.jp.
Division of Gastroenterology, Department of Medicine, CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (CU-UCSD cMAV), University of California, San Diego, CA, 92093-0956, USA. yosukek@ims.u-tokyo.ac.jp.
Institute for Global Prominent Research, Chiba University, Chiba, 260-8670, Japan. yosukek@ims.u-tokyo.ac.jp.
Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan. yosukek@ims.u-tokyo.ac.jp.
ORCID: 0000-0001-8588-4033

Masahiro Kiuchi (M)

Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.

Kiyoshi Hirahara (K)

Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.

Sayuri Murasaki (S)

Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.

Fujimi Arai (F)

Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.

Kumi Izawa (K)

Atopy Research Center, Juntendo University Graduate School of Medicine, Tokyo, 113-8421, Japan.

Ayako Kaitani (A)

Atopy Research Center, Juntendo University Graduate School of Medicine, Tokyo, 113-8421, Japan.

Kaoru Shimada (K)

Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.

Yukari Saito (Y)

Department of Innovative Medicine and Mucosal Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.

Shota Toyoshima (S)

Allergy and Immunology Research Project Team, Research Institute of Medical Science, Center for Allergy, Center for Medical Education, Nihon University School of Medicine, Tokyo, 173-8610, Japan.

Miho Nakamura (M)

Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.

Kumiko Fujisawa (K)

Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.

Yoshimichi Okayama (Y)

Allergy and Immunology Research Project Team, Research Institute of Medical Science, Center for Allergy, Center for Medical Education, Nihon University School of Medicine, Tokyo, 173-8610, Japan.

Jun Kunisawa (J)

International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan.

Masato Kubo (M)

Laboratory for Cytokine Regulation, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, 230-0045, Japan.
Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Chiba, 278-0022, Japan.

Naoki Takemura (N)

Department of Innovative Medicine and Mucosal Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Laboratory of Bioresponse Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka, 565-0871, Japan.

Satoshi Uematsu (S)

Department of Innovative Medicine and Mucosal Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Department of Immunology and Genomics, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

Shizuo Akira (S)

Laboratory of Host Defense, WPI Immunology Frontier Research Center, Osaka University, Osaka, 565-0871, Japan.
Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka, 565-0871, Japan.

Jiro Kitaura (J)

Atopy Research Center, Juntendo University Graduate School of Medicine, Tokyo, 113-8421, Japan.

Takao Takahashi (T)

Department of Pediatrics, Keio University School of Medicine, Tokyo, 160-8582, Japan.

Toshinori Nakayama (T)

Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.

Hiroshi Kiyono (H)

Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan. kiyono@ims.u-tokyo.ac.jp.
Department of Pediatrics, Keio University School of Medicine, Tokyo, 160-8582, Japan. kiyono@ims.u-tokyo.ac.jp.
Division of Gastroenterology, Department of Medicine, CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (CU-UCSD cMAV), University of California, San Diego, CA, 92093-0956, USA. kiyono@ims.u-tokyo.ac.jp.
Institute for Global Prominent Research, Chiba University, Chiba, 260-8670, Japan. kiyono@ims.u-tokyo.ac.jp.
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. kiyono@ims.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie orale › Orally desensitized mast cells form a...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Allergènes › Orally desensitized mast cells form a...
questionsmedicales.fr › Eucaryotes › Animaux › Orally desensitized mast cells form a...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Communication cellulaire › Orally desensitized mast cells form a...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Exocytose › Dégranulation cellulaire › Orally desensitized mast cells form a...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Désensibilisation immunologique › Orally desensitized mast cells form a...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Orally desensitized mast cells form a...
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Hypersensibilité alimentaire › Orally desensitized mast cells form a...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Tolérance immunitaire › Orally desensitized mast cells form a...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Orally desensitized mast cells form a...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Mastocytes › Orally desensitized mast cells form a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Orally desensitized mast cells form a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › Orally desensitized mast cells form a...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T régulateurs › Orally desensitized mast cells form a...